<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2021-12-23</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001822711</issuerCik>
        <issuerName>PARDES BIOSCIENCES, INC.</issuerName>
        <issuerTradingSymbol>PRDS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001884671</rptOwnerCik>
            <rptOwnerName>Autor Deborah M.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PARDES BIOSCIENCES, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>2173 SALK AVE., SUITE 250, PMB #052</rptOwnerStreet2>
            <rptOwnerCity>CARLSBAD</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92008</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>4.94</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2031-07-31</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>70390</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on the 29th day of each month following July 29, 2021, subject to a continued service relationship.</footnote>
    </footnotes>

    <remarks>Exhibit 24 - Power of Attorney

Effective immediately following the effective time of the merger pursuant to that certain Agreement and Plan of Merger dated as of June 29, 2021, as amended, by and among Pardes Biosciences Sub, Inc. (f/k/a Pardes Biosciences, Inc.), Issuer (f/k/a FS Development Corp. II), and certain other parties thereto, the reporting person became a director of the Issuer.</remarks>

    <ownerSignature>
        <signatureName>/s/ Elizabeth Lacy, attorney-in-fact</signatureName>
        <signatureDate>2021-12-27</signatureDate>
    </ownerSignature>
</ownershipDocument>
